Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 44.93% is 166% above its 5-year average of 16.90%, near the high end of its 5-year range (-303.80%–49.00%).
2.18% above its 12-month average of 43.97%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 49.00%.
OPERATING MARGIN
44.93%
OPERATING MARGIN AVG TTM
43.97%
OPERATING MARGIN AVG 3Y
28.16%
OPERATING MARGIN AVG 5Y
16.90%
OPERATING MARGIN AVG 10Y
0.00%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.18%
CURRENT VS 3Y AVG
+59.56%
CURRENT VS 5Y AVG
+165.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Krystal Biotech, Inc.
Market Cap
$9.63B
Operating Margin
44.93%
TTM Avg
43.97%
3Y Avg
28.16%
5Y Avg
16.90%
Market Cap
$9.66B
Operating Margin
5.69%
TTM Avg
5.75%
3Y Avg
6.18%
5Y Avg
6.20%
Market Cap
$9.87B
Operating Margin
8.32%
TTM Avg
1.27%
3Y Avg
9.53%
5Y Avg
14.21%
Market Cap
$9.93B
Operating Margin
9.08%
TTM Avg
10.48%
3Y Avg
12.70%
5Y Avg
14.08%
Market Cap
$10.03B
Operating Margin
8.52%
TTM Avg
8.41%
3Y Avg
8.37%
5Y Avg
8.78%
Market Cap
$9.21B
Operating Margin
3.61%
TTM Avg
7.20%
3Y Avg
11.56%
5Y Avg
12.63%
Market Cap
$10.13B
Operating Margin
13.33%
TTM Avg
15.23%
3Y Avg
16.08%
5Y Avg
17.45%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.63B | 44.93% | 43.97% | 28.16% | 16.90% |
| Vaxcyte, Inc. (PCVX)vs › | $9.63B | 0.00% | 0.00% | 0.00% | 0.00% |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 5.69% | 5.75% | 6.18% | 6.20% |
| Repligen Corporation (RGEN)vs › | $9.87B | 8.32% | 1.27% | 9.53% | 14.21% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 9.08% | 10.48% | 12.70% | 14.08% |
| Insulet Corp. (PODD)vs › | $9.33B | 16.89% | 16.20% | 12.06% | 10.90% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 8.52% | 8.41% | 8.37% | 8.78% |
| Bruker Corporation (BRKR)vs › | $9.21B | 3.61% | 7.20% | 11.56% | 12.63% |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 13.33% | 15.23% | 16.08% | 17.45% |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | -226.00% | -1280.12% | -51793.49% | -46507.49% |
Gross Margin
93.3%
Operating Margin
44.9%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 49.00% |
| 2026-03-31 | 46.14% |
| 2025-12-31 | 41.49% |
| 2025-09-30 | 42.30% |
| 2025-06-30 | 40.93% |
| 2025-03-31 | 41.02% |
| 2024-12-31 | 45.40% |
| 2024-09-30 | 26.76% |
| 2024-06-30 | 12.19% |
| 2024-03-31 | -14.77% |
| 2023-12-31 | 7.45% |
| 2023-09-30 | -303.80% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -1086.72% |
| 2019-03-31 | -805.15% |
| 2018-12-31 | -410.81% |
| 2018-09-30 | -1369.59% |
| 2018-06-30 | -1415.61% |
| 2018-03-31 | -1792.91% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
